Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Test Availability
Veracyte and Illumina will develop high-performing molecular tests as decentralized IVD tests on Illumina’s NextSeq 550Dx NGS instrument.
Read MorePosted by Andy Lundin | Nov 7, 2023 | Company News, Molecular Diagnostics |
Veracyte and Illumina will develop high-performing molecular tests as decentralized IVD tests on Illumina’s NextSeq 550Dx NGS instrument.
Read MorePosted by Andy Lundin | Nov 2, 2023 | Cancer |
The TruSightf Oncology 500 ctDNA v2 enables comprehensive genomic profiling of ctDNA from blood when tissue testing is not available.
Read MorePosted by Andy Lundin | Nov 1, 2023 | Cancer |
Researchers developed a highly sensitive blood test that detects a key protein produced by cancer cells, showing promise for early detection.
Read MorePosted by Andy Lundin | Oct 31, 2023 | Lung Cancer |
OncoHost developed a novel computational model for predicting significant immune-related adverse events in NSCLC patients.
Read MorePosted by Andy Lundin | Oct 24, 2023 | Cancer |
Researchers detected cancer earlier in individuals with Li-Fraumeni syndrome, an inherited condition with a high risk of developing cancer.
Read More